日韩情欲综合福利久久电影_榴莲视频在线观看卍_夜色福利院在线观看_国产精品 不卡_无码精品人妻一区二区三区在线_99韩国日本欧美国产_欧美一级特黄大片做受_午夜福利麻豆精品_人妻AV无码系列一_亚洲Aⅴ天堂Av天堂无码不卡

Industry Dynamics

Industry News

11-09

2020

Brilinta approved in the US to reduce the risk of stroke in patients with an acute ischaemic stroke or high-risk transient ischaemic attack

November 06, 2020 –AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institu……

10-30

2020

FDA Approves Expanded Indication for Merck’s KEYTRUDA? (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

October 25, 2020 -- MSD, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-2 therapy, as monotherapy for the treatment of adult patients with re……

10-09

2020

Kyowa Kirin Announces European Commission (EC) Approval of CRYSVITA? (burosumab) for the Treatment of X-Linked Hypophosphataemia (XLH) in Older Adolescents and Adults

October 5, 2020 – Kyowa Kirin Co., Ltd. today announced that the European Commission (EC) has approved CRYSVITA? (burosumab) for use in older adolescents and adults with the rare disease X-linked hypophosphataemia (XLH).……

09-29

2020

FDA Approves KALYDECO? (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age

September 26, 2020 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO? (ivacaftor) for use in children with cystic fibrosis (CF) ages four ……

09-07

2020

FDA approves additional doses of Trulicity? (dulaglutide) for the treatment of type 2 diabetes

Sept. 3, 2020 -- The U.S. Food and Drug Administration (FDA) today approved two additional doses of Eli Lilly and Company's (NYSE: LLY) Trulicity? (dulaglutide). The approval expands the label of once-weekly Trulicit……

08-31

2020

FDA approves Novartis Kesimpta? (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

August 20, 2020 ― Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta? (ofatumumab, formerly OMB257) as an injection for subcutaneous use for the treatment of relapsing forms of ……

< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 >

Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號(hào)-1